Artivion announces presentation of real world data from post market study of on-x® aortic heart valve replacement patients treated with low dose warfarin

Late-breaking science presented at the 37th european association for cardio-thoracic surgery annual meeting atlanta , oct. 5, 2023 /prnewswire/ -- artivion, inc. (nyse: aort), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its on-x aortic heart valve low inr post-market study presented in a late-breaking science session at the 37th european association for cardio-thoracic surgery (eacts) annual meeting in vienna, austria. real world interim results for all patients confirm that the on-x aortic valve remains safe and effective with low-dose warfarin.
AORT Ratings Summary
AORT Quant Ranking